tradingkey.logo
tradingkey.logo
Search

Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial

ReutersMar 19, 2026 11:31 AM

- Eli Lilly and Co LLY.N:

  • ELI LILLY: RETATRUTIDE SHOWED SIGNIFICANT REDUCTIONS IN A1C & WEIGHT IN FIRST PHASE 3 TRIAL FOR TYPE 2 DIABETES TREATMENT

  • ELI LILLY: RETATRUTIDE LOWERED A1C BY AVERAGE OF 1.7%-2.0% ACROSS DOSES AT 40 WEEKS IN TRANSCEND-T2D-1 TRIAL

  • ELI LILLY: PARTICIPANTS TAKING RETATRUTIDE 12 MG LOST AVERAGE OF 36.6 LBS

  • ELI LILLY: NO WEIGHT LOSS PLATEAU WAS OBSERVED WITH RETATRUTIDE

  • ELI LILLY: RETATRUTIDE SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI